A Single Infusion Study of DUR-928 in Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study to Assess the Safety, Tolerability and Pharmacokinetics of DUR-928 in Healthy Volunteers
INC Research
16 participants
Jul 26, 2016
Interventional
Conditions
Summary
This research project is being conducted to look at how safe and well tolerated a new drug called DUR-928 is when given as an intravenous infusion to healthy volunteers. The study will look at the study drug’s safety and tolerability when given as a single dose at 2 different dose levels. The pharmacokinetics of DUR-928 will also be studied; this is done by measuring the amount of DUR-928 in the blood at different times throughout the dosing periods, allowing us to evaluate how DUR-928 is handled by the body (for example how quickly it gets into the blood stream).
Eligibility
Inclusion Criteria6
- Be in good health as determined by medical history, physical examination, 12 lead ECG and clinical laboratory evaluations at screening;
- Weight at least 50kg and BMI between 18.0 kg/m2 and 30.0 kg/m2, inclusive;
- Male subjects must agree to use a medically acceptable method of contraception/birth control throughout the study duration and for 90 days after the study is completed;
- Female subjects must be of non-childbearing potential;
- Willing and be able to be admitted to the clinical study unit for 3 nights and 2 days;
- Able to abstain from alcohol and tobacco use during the trial.
Exclusion Criteria6
- Significant blood loss or donated blood in the 30 days prior to study participation
- Participation in an investigational drug study within 30 days prior to dosing.
- History of drug or alcohol abuse.
- Use of any medications, including OTC and herbal or nutritional supplements during the week prior to drug dosing
- Positive tests for HIV, hepatitis B/C, drugs of abuse or alcohol breath-test.
- Clinically significant abnormalities
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DUR-928 (powder for constitution): 30 mg/mL DUR-928 solution after constitution with sterile vehicle solution. Placebo: sterile vehicle solution. The sterile vehicle solution contains hydroxypropyl betadex in phosphate buffered water. Each subject will receive a single dose of either active DUR-928 or placebo. The constituted DUR-928 solution, or placebo vehicle, is appropriately diluted with glucose 5% intravenous solution to prepare the infusion solution. The dose will be administered via intravenous (IV) infusion. The doses of the intervention are described below per cohort: Cohort 1: 50 mg/100 mL DUR-928 or placebo (vehicle solution) administered over 2 hours via IV infusion Cohort 2: TBD* mg/100 mL of DUR 928 or placebo (vehicle solution) administered over 2 hours via IV infusion *Note: Dose level for Cohort 2 will be determined after review of safety, tolerability, and pharmacokinetic data of Cohort 1 and will not exceed 300 mg. Study participants will take part in only one cohort. All study participants will be confined to the study unit for the treatment period. Study staff will administer all doses.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12616000856415